Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

InMed Pharmaceuticals and BayMedica – executive interview

InMed Pharmaceuticals and BayMedica – executive interview

InMed Pharmaceuticals — 14 videos in collection

More on this equity

Earlier today, InMed Pharmaceuticals (INM) announced that it has signed a definitive agreement to acquire BayMedica, a leading commercial manufacturer of rare cannabinoids. Both companies have strong expertise in the manufacture of rare cannabinoids, with BayMedica largely focused on chemical and biosynthesis and InMed focused on developing IntegraSyn, its proprietary platform. The combined company will be a market leader in rare cannabinoid manufacturing with the flexibility to select the most appropriate and cost-effective method based on each different cannabinoid compound.

In this interview, InMed chief executive officer Eric Adams and BayMedica chief executive officer Dr Shane Johnson discuss their shared vision for the newly combined company.

< Previous
Next >

You may also be interested in these:

Healthcare

InMed Pharmaceuticals: Edison Open House Healthcare 2022

Healthcare

InMed Pharmaceuticals – Introducing the BayMedica team

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free